Krishna Institu.

Why is Krishna Institute of Medical Sciences Ltd falling/rising?

As of 19-Jul, Krishna Institute of Medical Sciences Ltd is experiencing a slight decline in its stock price, currently at 802.45, due to short-term underperformance and reduced trading activity. However, the company shows strong long-term performance with a year-to-date return of 32.18% and solid financial metrics, indicating resilience in the market.

As of 19-Jul, Krishna Institute of Medical Sciences Ltd is experiencing a slight decline in its stock price, currently at 802.45, reflecting a change of -0.7 (-0.09%). This decrease can be attributed to several factors highlighted in the provided data. <BR><BR>Firstly, the stock has underperformed in the short term, with a 1-week return of -1.59%, while the benchmark Sensex has gained 0.75% during the same period. Additionally, there is a notable drop in investor participation, as evidenced by a 54.85% decrease in delivery volume compared to the 5-day average, indicating reduced trading activity and interest in the stock.<BR><BR>Despite these short-term challenges, the company maintains a strong long-term performance, with a year-to-date return of 32.18%, significantly outperforming the Sensex, which has declined by 8.30% in the same timeframe. The stock has also shown robust performance over longer periods, with returns of 107.88% over three years and 213.36% over five years. <BR><BR>Moreover, the company benefits from high management efficiency, evidenced by a return on capital employed (ROCE) of 17.88%, and a strong ability to service its debt, indicated by a healthy EBIT to interest ratio of 12.59. High institutional holdings at 47.07% suggest that knowledgeable investors are backing the stock, which can provide some stability.<BR><BR>In summary, while the stock is currently facing a minor decline due to short-term underperformance and reduced trading activity, its strong long-term performance and solid financial metrics indicate a resilient position in the market.

Which are the latest news on Krishna Institu.?

What does Krishna Institu. do?

Krishna Institute of Medical Sciences Ltd is a small-cap company in the hospital industry, incorporated in 1973, with recent quarterly net sales of ₹1,075 Cr and net profit of ₹42 Cr as of March 2026. Key financial metrics include a market cap of ₹31,027 Cr, P/E ratio of 123.00, and a debt-equity ratio of 1.85.

Overview:<BR>Krishna Institute of Medical Sciences Ltd operates in the hospital industry and is categorized as a small-cap company.<BR><BR>History:<BR>The company was incorporated in 1973 as 'Jagjit Singh and Sons Private Limited' and later changed its name to 'Krishna Institute of Medical Sciences Private Limited' in 2004. Following its conversion to a public limited company, it adopted the name 'Krishna Institute of Medical Sciences Limited' on January 29, 2004. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1,075 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 42 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 31,027 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 123.00<BR>- Industry P/E: 60<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 1.85<BR>- Return on Equity: 11.03%<BR>- Price to Book: 13.94<BR><BR>Contact Details:<BR>Details: No Company Details Available<BR>Registrar Address: Not available.

How big is Krishna Institu.?

As of 10th June, Krishna Institute of Medical Sciences Ltd has a market capitalization of 31,027.00 Cr, with recent Net Sales of 3,904.60 Cr and a Net Profit of 241.40 Cr. Shareholder's Funds were 2,137.80 Cr, and Total Assets amounted to 5,676.10 Cr for the latest annual period ending March 2025.

As of 10th June, Krishna Institute of Medical Sciences Ltd has a market capitalization of 31,027.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 3,904.60 Cr and a Net Profit of 241.40 Cr.<BR><BR>For the latest annual period ending March 2025, the Shareholder's Funds were 2,137.80 Cr, and the Total Assets amounted to 5,676.10 Cr.

Who are in the management team of Krishna Institu.?

The management team of Krishna Institu includes Bhaskara Rao Bollineni (Chairman & Managing Director), Abhinay Bollineni (Executive Director & CEO), and several independent directors, bringing diverse expertise to the company.

The management team of Krishna Institu includes the following key members:<BR><BR>1. **Bhaskara Rao Bollineni** - Chairman & Managing Director<BR>2. **Abhinay Bollineni** - Executive Director & CEO<BR>3. **Dandamudi Anitha** - Whole-Time Director & Executive Director<BR>4. **Rajeswara Rao Gandu** - Independent Director<BR>5. **Saumen Chakraborty** - Independent Director<BR>6. **Pankaj Vaish** - Independent Director<BR>7. **Ratna Kishore Kaza** - Independent Director<BR>8. **J V Ramudu** - Independent Director<BR>9. **Y Prameela Rani** - Independent Director<BR>10. **Shantanu Rastogi** - Non-Executive Director<BR>11. **Adwik Bollineni** - Additional Director<BR><BR>This team brings a diverse range of expertise and leadership to the company.

Who are the peers of the Krishna Institu.?

Peers of Krishna Institu. include Max Healthcare, Fortis Health, Aster DM Health, Narayana Hrudaya, Global Health, Dr Agarwal's Health, Rainbow Children’s Hospital, and Jupiter Life Line. Krishna Institu. has good management risk and a 1-year return of 15.42%, higher than Max Healthcare but lower than Aster DM Health's 42.08%.

Peers: The peers of Krishna Institu. are Max Healthcare, Fortis Health., Aster DM Health., Narayana Hrudaya, Global Health, Dr Agarwal's Hea, Rainbow Child., Health.Global, Jupiter Life Lin.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare and Narayana Hrudaya, while Good management risk is found at Aster DM Health., Global Health, Krishna Institu., Rainbow Child., and Jupiter Life Lin. Average management risk is present at Fortis Health. and Dr Agarwal's Hea. For growth, Excellent growth is noted at Max Healthcare and Narayana Hrudaya, while Good growth is seen at Dr Agarwal's Hea. Below Average growth is reported for Aster DM Health., Global Health, Krishna Institu., Rainbow Child., and Jupiter Life Lin. Excellent capital structure is found at Max Healthcare and Global Health, Good capital structure is present at Fortis Health., Krishna Institu., Dr Agarwal's Hea., Rainbow Child., and Jupiter Life Lin, while Average capital structure is noted at Aster DM Health.<BR><BR>Return Snapshot: Aster DM Health. has the highest 1-year return at 42.08%, while Max Healthcare has the lowest at -14.68%. Krishna Institu.'s 1-year return is 15.42%, which is higher than Max Healthcare but lower than Aster DM Health. Additionally, the peers with negative six-month returns are Max Healthcare, Dr Agarwal's Hea., and Rainbow Child.

Should I buy, sell or hold Krishna Institute of Medical Sciences Ltd?

Are Krishna Institute of Medical Sciences Ltd latest results good or bad?

The latest results for Krishna Institute of Medical Sciences Ltd show strong revenue growth of 34.85% year-on-year, reaching ₹1,074.60 crore in Q4 FY26; however, net profit has plummeted by 58.25%, indicating significant profitability challenges due to rising operational costs and increased interest expenses. Overall, the results reflect underlying issues rather than a positive performance.

The latest results for Krishna Institute of Medical Sciences Ltd (KIMS) indicate a challenging financial situation. While the company achieved record revenues of ₹1,074.60 crore in Q4 FY26, reflecting a year-on-year growth of 34.85% and a sequential increase of 7.71%, the net profit has significantly declined. The consolidated net profit for the quarter was ₹42.50 crore, which represents a staggering 58.25% decrease compared to the same quarter last year and a 20.41% decline from the previous quarter.<BR><BR>Moreover, the operating margin has also taken a hit, contracting to 19.22%, down from 24.85% a year ago. This decline in profitability is attributed to rising operational costs and a substantial increase in interest expenses, which surged by 155% year-on-year.<BR><BR>Overall, while KIMS is experiencing strong revenue growth, the sharp drop in profitability and increasing operational challenges suggest that the latest results are more indicative of underlying issues rather than a positive performance. The company is facing significant hurdles, particularly related to its aggressive expansion strategy, which has not yet translated into sustainable profitability.

When is the next results date for Krishna Institute of Medical Sciences Ltd?

The next results date for Krishna Institute of Medical Sciences Ltd is 15 May 2026.

The next results date for Krishna Institute of Medical Sciences Ltd is scheduled for 15 May 2026.

Is Krishna Institu. technically bullish or bearish?

As of December 1, 2025, the trend is mildly bullish due to daily moving averages, but caution is advised as weekly MACD and KST are bearish, despite a bullish weekly RSI and mixed signals from Bollinger Bands.

As of 1 December 2025, the technical trend has changed from sideways to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating bullish momentum. However, the weekly MACD and KST are both mildly bearish, which suggests some caution. The weekly RSI is bullish, supporting the positive outlook, while the Bollinger Bands show a mixed signal with a bullish monthly perspective. Overall, the strength of the bullish sentiment is tempered by the bearish signals in the weekly indicators.

Is Krishna Institu. overvalued or undervalued?

As of November 26, 2025, Krishna Institute is considered very expensive with a PE ratio of 83.68, significantly higher than peers like Apollo Hospitals and Max Healthcare, indicating it is overvalued despite a 14.51% return over the past year compared to the Sensex's 7.01%.

As of 26 November 2025, the valuation grade for Krishna Institute has moved from expensive to very expensive. This indicates that the company is currently overvalued. Key ratios highlight this situation, with a PE ratio of 83.68, an EV to EBITDA of 38.97, and a Price to Book Value of 12.07. <BR><BR>In comparison to peers, Krishna Institute's valuation is notably higher than that of Apollo Hospitals, which has a PE ratio of 63.6 and an EV to EBITDA of 33.45, indicating that Krishna is trading at a significant premium. Additionally, Max Healthcare, another peer, has a PE ratio of 80.02, further emphasizing the elevated valuation of Krishna Institute. While the company has outperformed the Sensex over the past year with a return of 14.51% compared to the Sensex's 7.01%, the current valuation suggests caution for potential investors.

How has been the historical performance of Krishna Institu.?

Krishna Institu has demonstrated consistent growth from March 2020 to March 2025, with net sales increasing from INR 1,122.65 crore to INR 3,035.00 crore, and profit after tax rising from INR 115.07 crore to INR 414.50 crore. The company's total assets and cash flow from operating activities also significantly improved during this period.

Answer:<BR>The historical performance of Krishna Institu shows a consistent growth trajectory in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Krishna Institu's net sales have increased significantly from INR 1,122.65 crore in March 2020 to INR 3,035.00 crore in March 2025, demonstrating a strong upward trend. The total operating income followed a similar pattern, reaching INR 3,035.00 crore in March 2025, up from INR 1,122.65 crore in March 2020. The company's operating profit (PBDIT) also saw substantial growth, rising from INR 251.08 crore in March 2020 to INR 814.60 crore in March 2025. Profit before tax increased from INR 140.53 crore in March 2020 to INR 557.90 crore in March 2025, while profit after tax rose from INR 115.07 crore to INR 414.50 crore in the same period. The company's total assets grew from INR 1,194.47 crore in March 2020 to INR 5,676.10 crore in March 2025, indicating a robust expansion in its asset base. Total liabilities also increased, from INR 1,194.47 crore to INR 5,676.10 crore, reflecting the company's growing financial commitments. Cash flow from operating activities improved from INR 201.00 crore in March 2020 to INR 581.00 crore in March 2025, while net cash inflow turned positive at INR 9.00 crore in March 2025, compared to a net outflow in previous years. Overall, Krishna Institu has shown strong growth in sales, profits, and asset accumulation over the past five years.

Who are the top shareholders of the Krishna Institu.?

The top shareholders of Krishna Institu include promoter Bhaskara Rao Bollineni with 26.27%, mutual funds at 25.35%, foreign institutional investors at 15.45%, and the SBI Small Cap Fund as the largest public shareholder with 6.31%. Individual investors collectively hold 11.24% of the shares.

The top shareholders of Krishna Institu include the promoters, who hold a majority stake in the company. The promoter with the highest holding is Bhaskara Rao Bollineni, with a significant 26.27%. Additionally, mutual funds hold 25.35% of the shares through 24 different schemes, while foreign institutional investors (FIIs) account for 15.45% with 171 FIIs involved. The highest public shareholder is the SBI Small Cap Fund, which holds 6.31%. Individual investors collectively hold 11.24% of the shares.

Has Krishna Institu. declared dividend?

No Dividend History Available